The paradox that group-specific neutralizing antibodies (NA) exist in the majority of human immunodeficiency virus type 1 (HIV-1)-infected patients, whereas the NA response against autologous HIV-1 virus isolates is highly type-specific, motivated us to study the type-and group-specific NA responses generated upon presentation of escape virus, and the viral epitopes involved in the escape. Patients with demonstrable escape virus all developed group-specific NA, which were detectable after a delay and disappeared prior to disease development. The sera tested inhibited the binding of recombinant soluble gpl20mB to cell-associated CD4, but group-specific virus neutralization required binding of NA to HIV-1 prior to viral attachment to target cells.
The paradox that group-specific neutralizing antibodies (NA) exist in the majority of human immunodeficiency virus type 1 (HIV-1)-infected patients, whereas the NA response against autologous HIV-1 virus isolates is highly type-specific, motivated us to study the type-and group-specific NA responses generated upon presentation of escape virus, and the viral epitopes involved in the escape. Patients with demonstrable escape virus all developed group-specific NA, which were detectable after a delay and disappeared prior to disease development. The sera tested inhibited the binding of recombinant soluble gpl20mB to cell-associated CD4, but group-specific virus neutralization required binding of NA to HIV-1 prior to viral attachment to target cells.
Consecutive escape virus isolates were tested for sensitivity to neutralization by heterologous sera. Only minor differences were demonstrated, suggesting that the majority of the change in neutralization sensitivity is driven by the selective pressure of type-specific NA. Furthermore, no differences were observed in sensitivity to neutralization by anti-carbohydrate neutralizing monoclonal antibodies or the lectin concanavalin A, indicating a conserved nature of certain carbohydrate neutralization epitopes during escape. Finally the V3 sequence of three sets of consecutive virus isolates were analysed revealing amino acid mutations in V3 sequences of all escape virus isolates. The biological significance of these variations was confirmed further by the demonstration of changes in sensitivity to neutralization by anti-V3 monoclonal antibodies. These results strongly suggest a participation of the NA response against the V3 loop in the immunoselection of escape virus.
Introduction
During human immunodeficiency virus type 1 (HIV-1) infection, virus-neutralizing antibodies (NA) are developed. Although NA are associated with the healthy carrier state, the infection persists, and most if not all HIV-l-infected individuals eventually develop AIDS (Arendrup et al., 1992b; Robert-Guroff et al., 1985; Weiss et al., 1985) .
The apparent failure of the immune system to control the HIV-1 infection effectively may be due in part to changes in the HIV-1 population driven by immunoselection by NA (Albert et al., 1990; Arendrup et al., 1992a; McKeating et al., 1989; Reitz et al., 1988; Robert-Guroff et al., 1986; Tremblay & Wainberg, 1990) . Escape virus emerges as a repeated phenomenon, and the NA response against the autologous virus isolates is highly type-specific. Thus, sera from HIV-1-infected patients in most cases do not posses detectable neutralizing activity towards later escape virus although they can neutralize virus isolated earlier (Arendrup et al., 1992a) . Previous studies have shown that the majority of HIV-l-infected individuals develop group-specific NA, defined as NA against heterologous virus strains, although often only in low titres (Arendrup et al., 1992b; Robert-Guroff et al., 1985; Weiss et al., 1985) . These are probably directed against the CD4-binding domain of gpl20, and prevent infection by inhibiting the binding of gpl20 to the CD4 receptor (Berkower et al., 1991 ; Kang et al., 1991) . The apparent discrepancy between the two findings that on the one hand the majority of HIV-1-infected patients develop group-specific NA, while on the other the NA response against autologous virus isolates is highly type-specific without NA against later isolated escape virus, motivated us to study in more detail the neutralization response generated upon presentation of escape virus during HIV-1 infection, i.e. the epitope specificity, the CD4-binding inhibition (BI) properties, We have therefore determined the difference between consecutive escape virus isolates in sensitivity to groupspecific NA, to anti-carbohydrate neutralization MAbs, in V3 sequences, and in sensitivity to neutralization by anti-V3 MAbs.
Methods

Patients and sera.
Five patients with previously demonstrated production of escape virus during HIV-1 infection (Arendrup et al., 1992a) were included in the study. Three seroconverted during a follow-up study of seronegative homosexual individuals (patients 1 to 3). The time of seroconversion was estimated as the median of the interval between the last HIV antibody-negative and first HIV antibody-positive serum sample. Two patients had been HIV antibodypositive at least 5 to 6 years and were included as late-stage patients (patients 4 and 5). Serum samples and heparinized blood for virus isolation were collected sequentially over a 3 year period.
Serum from five different healthy HIV-l-infected patients with CD4 cell counts above 0.5 x 109 cells/1 were included for determinations of the sensitivity of consecutive virus isolates to heterologous NA. The presence of HIV-1 antibodies was indicated by ELISA (DuPont) and confirmed by Western blotting (DuPont). All sera were stored at -20 °C, heat-inactivated for 30 min at 56 °C, and sterilized by filtration (02 lam filter pore, Gelman) prior to use in neutralization assays.
Cells. Peripheral blood mononuclear cells (PBMCs) for virus propagation, infectivity titration and neutralization assays were obtained by Ficoll-Paque centrifugation of mixed buffy coats from normal donors (four donors per separation). PBMCs were phytohaemagglutinin (PHA)-stimulated for 72 h in RPMI-1640 medium supplemented with 10 % heat-inactivated fetal calf serum (FCS), glutamine, HEPES, gentamicin and penicillimstreptomycin prior to use. All PBMC assays were done in RPMI-1640 with 10% FCS, glutamine, antibiotics and interleukin 2 (IL-2; 20 international units per ml, Boehringer Mannheim).
The T4 lymphocyte cell lines MT-4 (Harada & Yamamoto, 1985) and H9 uninfected and chronically infected with the HTLV-IIIB strain of HIV-1 were cultured at 37 °C in 5% CO2, using RPMI-1640 with 10% FCS, glutamine and antibiotics (growth medium). Cells were maintained at a concentration of 0.2 to 1 x 106 cells per ml and medium was changed twice weekly.
Virus isolation and propagation. Virus was isolated by cocultivation of purified CD4 + lymphocytes from Danish patients as previously described (Arendrup et al., 1992b; Gaub et al., 1987; Nielsen et al., 1991) .
Propagation of consecutive Danish low-passage field isolates (Arendrup et al., 1992a) , the Danish laboratory-adapted isolate FICPH-22 (Adrendrup et al., 1992b; Gaub et al., 1987) and the laboratory strain HTLV-IIIB was done in cultures of PHA-stimulated PBMCs maintained with IL-2. Maximum antigen titres determined by antigen-capture ELISA were reached within 1 to 3 weeks and cultures were kept for 4 to 6 weeks. Virus pools were made from the supernatants with the highest antigen titres, and the infectivity of the virus pools was determined by an IDs0 assay as described below.
Cell-free infectious virus isolates from lymphocyte cultures were passaged in MT-4 cell cultures twice, and supernatants were evaluated for production of antigen and infectious virus titre as described below. Pools from first and second passage MT-4 cultures were made from supernatants with the highest infectious titre. All virus preparations were filtered (0.2 gin), and stored in aliquots at -70 °C.
Virus infectivity titration assay. Determinations of infectious titre in homologous virus isolates (sequential virus isolates from each patient) were done simultaneously using the same pool of PHA-stimulated PBMCs. The infectivity of the virus pools was determined by endpoint titration in a microtitre assay as previously described, with eight replicates per dilution and overnight inoculation, for subsequent determinations of NA in serum (Arendrup et al., 1992a) . Additional titration of virus pools in a multi-dish assay, for subsequent determinations of the neutralizing activity of anti-V3 MAbs, was done as follows. Briefly, 2.5 x 108 PHA-stimulated PBMCs were incubated 2 h at 37 °C in twofold dilutions of the virus pool. After extensive washing the cells were transferred in quadruplicates to 24-well multidish plates at 5 x 105 cells/well in a total of 1 ml medium. Virus production at day 7 was measured by HIV-1 antigen-capture ELISA. The cutoff value was defined as twice the mean of four negative controls. The 50 % cell culture infectious dose (CCIDs0) titre was defined as the reciprocal of the dilution that resulted in 50 % of the cultures being positive and was calculated by interpolation (Reed & Muench, 1938) .
Virus preparations from MT-4 cultures were titrated in parallel twice in MT-4 cells. Twofold dilutions of virus were used to inoculate 1 x 108 MT-4 cells into a total of 600 gl growth medium for 2 h at 37 °C. After extensive washing, the cells were transferred in quadruplicates to a 24-well cell culture plate (2 x 105 cells per well in 1 ml growth medium). Cultures were maintained for 7 days at 37 °C, 5 % CO 2. HIV antigen in culture supernatants was measured on day 4 by HIV-1 antigencapture ELISA and the CCIDs0 of each virus preparation was calculated by interpolation (Reed & Muench, 1938) .
Neutralization assay. In neutralization experiments using PBMCs as target cells all sera to be compared were tested against all homologous virus isolates on the same day using the same pool of PHA-stimulated lymphocytes. A standard virus dilution containing 25 CCIDs0 units/ml was used as virus inoculnm, as previously described with l h preincubation of serum and virus, eight replicates per dilution and overnight inoculation (Arendrup et al., 1992 a, b) . The neutralizing titre was defined as the reciprocal of the dilution reducing the number of infected cultures to 50 %, and was calculated by interpolation (Reed & Muench, 1938) .
For titration of the neutralizing capacity of anti-V3 MAbs, an infectivity inhibition multi-dish assay was used. Briefly, 25 CCIDs0 of each virus was preincubated for 1 h at 37 °C in a dilution series of anti-V3 MAb and used to inoculate 2.5 x 106 PHA-stimulated PBMC in 600 gl growth medium for 2 h at 37 °C. After extensive washing, the cells were transferred in quadruplicates to a 24-well cell culture plate (5x 105 cells per well in l ml growth medium). Cultures were maintained for 7 days at 37 °C, 5% CO~. HIV antigen in culture supernatants was measured at days 4 and 7 by HIV-1 antigen-capture ELISA. Antigen concentration was expressed relative to the antigen concentration at corresponding days in control cultures inoculated with untreated HIV.
In neutralization experiments using MT-4 cells as target cells, 25 CCID60 of each virus was preincubated for 1 h at room temperature in dilutions of concanavalin A (Con A), MAb or control serum and used to inoculate 1 x 105 MT-4 cells in 600 gl growth medium for 2 h at 37 °C. After extensive washing, the cells were transferred in quadruplicates to a 24-well cell culture plate (2 x 105 cells per well in 1 ml growth medium). Further procedures were as described above.
Inhibition of infectivity before and after virus adhesion. Dilutions of
heat-inactivated test serum, anti-V3 control MAb or growth medium were preincubated with 50 CCID~0 HTLV-IIIB for 1 h at 4 °C. These HIV preparations were then added to 1 x 106 MT-4 cells in 500 gl growth medium and incubated for 1 h at 4 °C to allow adhesion but prevent penetration (Hansen et al., 1991 a; Marsh & Helenius, 1989) .
After washing twice in cold medium, antibody-pretreated HIV-1-inoculated cells were resuspended in growth medium, and mock-treated HIV-1-inoculated cells in dilutions of serum, MAb or growth medium. After another 1 h incubation at 4 °C the cells were washed five times in medium, resuspended in 5 ml of growth medium and plated onto 24-well multi-dish plates in quadruplicates. Cell concentration and HIV antigen production were evaluated on days 4 and 7 as described above.
MAbs. The following anti-carbohydrate MAbs were used in infectivity inhibition assays: 1E3 (IgG2a, Tn epitope), TKH6 (IgM, Tn epitope), 1C12 (IgM, reacting with Tn and sialosyl-Tn epitopes), TKH2 (IgG1, sialosyl-Tn), B72.3 (IgG1, sialosyl-Tn), HH8 (IgM, T), AH6 (IgM, LeY), AH21 (IgM, histo-blood group A epitope) and 5F4 (IgM, reacting with Tn epitope). MAbs used were supernatants of hybridoma cultures grown in RPMI-1640 with 5 to 15 % FCS. TKH6, HH8, AH6 and AH21 were used without further treatment, whereas 1C12, 1E3, TKH2, B72.3 and 5F4 were dialysed against PBS and sterile filtered (0.2 lam) before use.
The following MAbs directed against the V3 looPoOf HIV-1 were used: 110.4 (Genetic Systems), F58/H3 and P4/D10 (Akerblom et al., 1990 ) against the HTLV-IIIB V3 loop of gpl20, and SP.SF2:104 (IgG2a, kappa) against the SF2 V3 loop of gp120 (epitope amino acids SIYIGPGRAF). These MAbs neutralize their respective HIV-1 strains in the infection assay used.
CD4-binding inhibition assay.
Two separate assays for determinations of CD4 BI antibodies were used. First, patient sera were assayed for their ability to block binding between gp 120 and cell-associated CD4 in a kinetic assay (B. Svennerholm, unpublished results), gpl20, purified from green monkey kidney cells infected with a gpl20-encoding recombinant virus (Bolmstedt et al., 1991) , was allowed to bind to CD4 ÷ HeLa cells with or without preincubation with dilutions of serum for 15 rain at 37 °C. The amount of gpl20 adsorbed to the cell surface was measured directly in an ELISA system using the anti-V3 (IIIB) MAb F58/H3 as detecting antibody (negative control CD4-HeLa cells). The BI titre was defined as the reciprocal of the serum dilution resulting in a 50% reduction of the totally adsorbed gp120 without antiserum.
Secondly, the CD4 BI properties were confirmed using 96-well immunoplates precoated with soluble (s) recombinant CD4 (NenQuest, DuPont) together with biotinylated recombinant gpl20 (IIIB) (Neosystem Laboratoire). Briefly, the sCD4-coated wells were incubated with a dilution series of serum (1:50 to l:5000) and biotinylated gp 120 (25 ng per well) for 18 h. After washing, horseradish peroxidase conjugated to avidin was added (diluted 1 : 1000). Inhibition of CD4 gpl20 binding was evaluated relative to wells without serum, and a reduction of at least 50% in absorbance was regarded as a requirement for inhibition.
V3 sequencing assay. DNA was extracted from 1.5 x 106 to 2 x 106 cells and PCR was run in a three primer nested configuration, as described earlier (S6nnerborg et al., 1990, 1991) . The primer sequences are located in the V3 region at HIV-SF2 genomic positions 7025 to 7043, 7332 to 7354 and 7474 to 7492. Once the position of the desired amplified product was detelTnined (340 bp), the remaining amplified DNA was purified and used in the sequencing reaction.
Amplified DNA products were electrophoresed in a 2-5 % agarose gel containing ethidium bromide and run at 40 V for at least 2 h. The gel fragment containing the target DNA was cut out. The DNA was then eluted and purified using commercially available kits (Geneclean II Kit, Biol01 Inc.), following the manufacturers' recommendations.
Direct sequencing of the dsDNA template was performed using the upstream sense PCR primer in the reaction. A commercial multi-well microtitre plate DNA sequencing system (Amersham) for performing the dideoxynucleotide chain termination method was used. The sequence information was stored, edited and translated to protein sequence using the microcomputer programs DNASIS and PROSIS (Pharmacia-LKB).
Results
Group-specific neutralizing immune response upon presentation of escape virus during HIV-1 infection
To investigate whether a group-specific neutralization response was generated, despite the fact that the NA response against autologous virus isolates was highly type-specific, and thus did not include escape virus isolated later, the sera from five patients known to develop escape virus (Table 1) (Arendrup et al., 1992a) were tested for neutralizing capacity against two distantly related HIV-1 strains. Independently of the presence or absence of autologous NA, the three patients followed from the time of seroconversion (patients 1 to 3) as well as the two patients with HIV-I infection 5 to 6 years prior to inclusion in this study (patients 4 and 5) developed group-specific NA against the laboratory strain HTLV-IIIB and the Danish field isolate FICPH-22 (Table 2) . A delay was observed before the appearance of group-specific NA (patients 1 to 3), and these declined or disappeared before disease development (patients 1 and 3), in agreement with earlier observations (Arendrup et al., 1992 b) .
It has been reported previously that group-specific NA are mainly targeted against the CD4-binding domain of gpl20 and thus prevent infection by inhibition of virus binding to the CD4 receptor (Berkower et al., 1991; Kang et al., 1991) . We therefore asked whether the * Four sera from each of five patients analysed for neutralizing capacity against autologous virus isolates. Titres were defined as the reciprocal of the serum dilution reducing the number of viruspositive cultures to 50%. Data previously presented in Arendrup et al. (1992a) . * Titres of NA defined as the reciprocal of the serum dilution reducing the number of virus-positive cultures to 50 %, and the titres of CD4 BI defined as the reciprocal of the highest dilution reducing the binding of soluble gpl20 to cell-associated CD4 (twofold serum dilutions 1:20 to 1:320) by 50 %, when compared to normal serum control.
t -, Titre below 20.
group-specific NA, demonstrated here, were associated with CD4 BI antibodies. Three sera with NA against the laboratory strain HTLV-IIIB as well as against the field isolate FICPH-22 (serum no. 3 from each of the patients 1 to 3) and three sera without detectable NA against HTLV-IIIB (serum no. 4 from each of the patients 1 to 3) were analysed for the capacity to inhibit recombinant soluble gpl20ii m (rs-gpl20mB) binding to cell-associated CD4. As illustrated in Table 3 the HTLV-IIIB neutralizing as well as the HTLV-IIIB non-neutralizing sera inhibited rs-gpl20nm binding to CD4 in titres ranging from 20 to above 320. The sera were analysed further for the capacity to inhibit binding of biotinylated gp120 to sCD4, and correspondingly the two sera from patient 1 inhibited CD4 binding equally well, whereas an increase in BI titre was found from sera 3 and 4 from patient 2 and no inhibition was found with the two sera from patient 3. Thus, no correlation was found between the BI titre and the capacity to neutralize the corresponding HTLV-IIIB virus strain, e.g. in patient 2 the CD4 BI titre increased, whereas the NA against the corresponding HTLV-IIIB strain declined from above 180 to 20. Since neutralizing as well as non-neutralizing sera apparently inhibited the binding of rs-gpl20 to cellassociated CD4, we asked whether the group-specific neutralizing activity against HTLV-IIIB happened before or after the binding of virions to the target cells. One serum (serum 4 from patient 5) with high titre group-specific NA against HTLV-IIIB was tested for the capacity to neutralize HTLV-IIIB before and after viral attachment to the target cell. As seen in Fig. 1, significant inhibition of the infection was seen only when the serum was allowed to neutralize the virus before attachment to the target cells. In contrast the anti-V3 (IIIB) MAb, F58, neutralized infection equally well when added either before or after virus adhesion to the target cells. This indicates that the group-specific neutralization requires binding of NA to HIV-1 prior to virus binding to the target cell, in agreement with earlier observations that the CD4-binding domain of gpl20 elicits group-specific NA.
Conserved and variable epitopes during immunoselection of escape virus
To investigate whether group-specific neutralization domains, recognized by distantly related heterologous sera, were changed during the immunoselection of escape virus, three consecutive virus isolates from patient 3 with early HIV-1 infection and three consecutive virus isolates from patient 4 with later stage HIV-1 infection were analysed for sensitivity to neutralization by sera from five different healthy HIV-l-infected patients (Table 4 ). The three virus isolates from the late stage patient (patient 4) showed equal sensitivity to neutralization by the heterologous sera. The escape virus from the early stage patient (patient 3) showed a decline in sensitivity to neutralization to two of the heterologous sera (sera c and d, titres declining from 104 to 35) and equal sensitivity to neutralization by the remaining three sera (sera a, b and e). Thus, the development of escape virus due to immunoselection mainly depends on changes in regions * Three consecutive virus isolates from each of the patients 3 and 4 analysed for sensitivity to neutralization by five heterologous sera and four autologous sera. Titres were defined as the reciprocal of the serum dilution reducing the number of virus-positive cultures to 50 %.
~ Sera from five healthy HIV-infected Danish patients (Pt) a to e.
:~ Four sera from patient 3 and patient 4 respectively (Arendrup et al., 1992a) . § -, Neutralization titres below 20. other than those containing group-specific neutralizing epitopes recognized by heterologous sera.
The possible involvement of carbohydrate neutralization epitopes in viral escape from serum neutralization was studied using a panel of anticarbohydrate MAbs and the lectin Con A. Since the glycosylation of viral proteins is dependent not only on amino acid composition of the protein but also on the glycosylation system of the target cell, the consecutive isolates were passed to the same immortalized cell line. It was not possible to rescue free infectious virus from the H9 cultures, neither after cell-free passage of virus nor after cocultivation of infected PBMCs with H9 cells. However, four of the 15 isolates could productively infect MT-4 cells and cell-free transmission, including all three isolates from patient 3. The virus isolates produced in MT-4 cells were tested for sensitivity to neutralization by autologous serum and showed no difference from the original virus produced in PBMC; that is, the third virus isolate showed reduced sensitivity to autologous serum (Table 5) . Initially MAbs against Tn (1E3 IgG2A, TKH6 IgM), against both Tn and sialosyl-Tn (1C12 and 5F4 both IgM), against sialosyl-Tn (TKH2 and B72.3 both IgG1), against T (HH8 IgM), against LeY (AH6 IgM), and against histo-blood group A (AH21 IgM) were tested undiluted for neutralizing activity against the second isolate from patient 3. MAbs against Tn and sialosyl-Tn were found to possess varying degrees of neutralizing activity (Fig. 2) . One anti-Tn MAb (1E3) and one anti-sialosyl-Tn MAb (B72.3) were chosen for further analysis. These MAbs and the lectin Con A specific for N-linked complex and high mannose-type glycans were tested for neutralizing capacity against all three isolates. No significant difference in sensitivity to neutralization by the two anti-carbohydrate MAbs and Con A was observed between the three virus isolates, despite the persistent difference in sensitivity to neutralization by autologous patient serum (serum 3 diluted 1:50), confirming the previously demonstrated conserved nature of these epitopes even during immunoselection (Table 5 ). The finding that neither neutralization epitopes recognized by group-specific heterologous sera nor neutralization carbohydrate epitopes recognized by two anti-carbohydrate MAbs or by the lectin Con A were significantly involved in the changes leading to development of escape virus suggested that neutralization epitopes recognized by type-specific NA were perhaps responsible for the evolution of escape virus. The highly variable V3 region of gpl20 induces production of a strong but type-specific NA response (Palker et al., 1988; Zwart et al., 1991 this region could account for the emergence of escape virus, the V3 loop was sequenced from three consecutive virus isolates from each of three patients. The amino acid sequences are listed in Fig. 3 . As can be seen, mutations in the V3 sequence were detected in patient 2 simultaneously with the development of the first and the second escape virus, in patient 4 also simultaneously with the development of the escape virus, and in patient 3 in the sequence of the virus isolate taken just before the development of the escape virus. These findings suggest that the variations in sensitivity to neutralization by autologous sera may be caused by changes in the V3 region. To test this hypothesis, anti-V3 MAbs against the HTLV-IIIB and SF2 HIV strains were tested for their neutralizing capacity against initial and escape virus isolates. All three virus isolates from patient 4 resisted neutralization by anti-V3 HTLV-IIIB MAbs (P4/D10 and 110.4). However, the third virus isolate, which in neutralization experiment was found to be an escape virus, was sensitive to neutralization with anti-V3 SF2 HIV MAb (SP.SF2:104) in contrast to the first and second virus isolates from this patient, indicating that the mutation in this V3 region resulted in a change in neutralization sensitivity.
Discussion
A major challenge in the effort to develop a vaccine is to overcome the antigenic variation of HIV-1 and generate a broadly reacting group-specific neutralization response. In this study we dissected the nature of the type and group specificity of the neutralization response generated during in vivo HIV-1 infection• Type-specific NA was defined here as antibodies able to neutralize only a few HIV-1 isolates, and group-specific NA as antibodies able to neutralize distantly related HIV-1 strains, even though these have not been presented to the immune system. Furthermore, we studied the involvement of CD4 BI antibodies in virus neutralization, and finally we investigated the conserved and variable nature of various neutralization domains during in vivo immunoselection of escape virus.
In extension of a recent study, in which we demonstrated the highly type-specific nature of the neutralization response against autologous virus isolates ( Arendrup et al., 1992a) , we show here that, when assayed against two distantly related HIV-1 strains, group-specific NA were present even in sera without detectable NA against autologous escape virus. The coexistence of group-specific NA with escape virus resistant to autologous neutralization suggests that the virus may be able to escape not only from NA traditionally regarded as highly type-specific but also from NA against neutralization epitopes conserved among distantly related virus strains. Group-specific NA are generally regarded as mediating a broadly reacting neutralization and thus being able to confer protection if generated upon immunization/vaccination. However, the important finding that escape virus, although sensitive to neutralization by heterologous NA, resists neutralization by the group-specific NA present in autologous serum, illustrates that the epitopes targeted by group-specific NA are most likely conserved only when not subjected to an immunoselection pressure. Thus, it is possible that the benefit of post-exposure immunization of HIV-l-infected individuals will be limited by a high capacity of the virus to escape from NA also against epitopes considered as conserved.
It has recently been reported by several groups that the group-specific neutralizing activity in serum is found in the antibody fraction directed against the CD4-binding domain of gpl20 (Berkower et al., 1991; Kang et al., 1991) , and great attention has been paid to this conserved conformation epitope. We therefore determined whether the group-specific neutralizing sera in our study inhibited CD4 binding. Surprisingly, inhibition of the binding of rs-gpl20 to cell-associated CD4 as well as to sCD4 was observed independent of the presence or absence of neutralizing activity against the corresponding HTLV-IIIB. This finding confirms the findings of Schnittmann et al. (1988) and Benjouad et al. (1992) who also documented a very high frequency of CD4 BI antibodies without correlation to the presence of NA. If antibodies are generated that are able to inhibit the binding of infectious virus to the CD4 receptor without neutralizing the infectivity of the virus, the generally accepted nature of HIV-1 neutralization is challenged, and involvement of secondary receptors must be reconsidered. One possible explanation of this apparent paradox may be that, on presentation of free gpl20 during natural HIV-1 infection (Oh et al., 1992) , anti-gpl20 antibodies with CD4 BI properties are elicited against epitopes not presented by membrane-associated oligomeric gpl20. Such antibodies may therefore be able to inhibit binding of soluble gpl20 to CD4 without interfering with the binding of virus-associated gp120. Alternatively, although sufficient for the inhibition of CD4 binding in vitro, the CD4 BI antibodies may not be present in sufficient amounts to neutralize HIV infection. Irrespective of the reason for the discrepancy between CD4 BI antibodies and NA, the finding presented here illustrates the necessity for cation when using CD4 BI antibodies to evaluate success in vaccine trials.
The study of HTLV-IIIB neutralization before and after virus attachment to the target cell demonstrated that neutralization was obtained only when the serum was added before virus attachment, in contrast to the anti-V3 MAb which caused virus neutralization also when the virus had been already allowed to attach. This result suggests strongly that the neutralization was mediated by prevention of virus binding to the target cell, i.e. by reacting with the CD4-binding domain on gpl20. However, the possibility of post-binding events requiring binding of antibody before virus attachment cannot be excluded.
Our study of the conservation of various neutralization epitopes during in vivo immunoselection of escape virus documents the conserved nature of (i) epitopes recognized by a panel of heterologous neutralizing human sera and of (ii) primitive O-linked carbohydrate neutralization epitopes recognized by anti-Tn and antisialosyl-Tn MAbs, and the N-linked complex or high mannose type of carbohydrate neutralization epitopes recognized by Con A. Although it cannot be excluded that HIV-1 might be able to escape from NA against these epitopes if subjected to a relevant immunoselection pressure, the highly conserved nature, particularly of the carbohydrate neutralization epitopes of HIV-2 also (Hansen et al., 1991a, b) , suggests that these epitopes may be critical to the virus and hence to be some of the most promising vaccine candidates.
In contrast to the conserved nature of the neutralization epitopes discussed above, sequencing of the V3 region of consecutive virus isolates revealed mutations in this region between initial and escape virus in all sets of isolates examined. In one case the mutation was observed in an isolate collected before the escape virus. However, it is likely that this observation represents a time when the circulating PBMC population contains a mixture of initial and escape virus. The biological significance of the mutations in the V3 region could in one case be confirmed further by a change in sensitivity to the anti-V3 SF2 MAb. Thus, these observations confirm the highly variable nature of the V3 loop, and strongly suggest that the NA response against this epitope constitutes a strong immunoselective force for generation of escape virus in vivo.
